Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.

Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.

Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.

Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.

Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.

Abstract: An airbag housing can be detachably fixed to at least one abutting wall area via at least one fixing device. The airbag housing has a plurality of tongues protruding laterally outwards on at least two opposing sides. The tongues arranged next to one another on one side are each spaced from the next by the width of at least one tongue. For the tongues of the airbag housing, a fixing frame on the dashboard has corresponding undercuts, and therefore the fixed airbag module is connected to the tongues in a form-locking manner in the undercuts.

Abstract: The present invention relates to a method for casting building material to form a construction element using a computer-controlled apparatus. The method comprises the steps of: moving the material deposition head and selectively depositing material, to fabricate a formwork; pouring building material in contact with at least a portion of the formwork; at least partially curing the building material, thereby forming the construction element; and removing at least a portion of the formwork from the construction element.

Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.

Abstract: An airbag housing can be detachably fixed to at least one abutting wall area via at least one fixing device. The airbag housing has a plurality of tongues protruding laterally outwards on at least two opposing sides. The tongues arranged next to one another on one side are each spaced from the next by the width of at least one tongue. For the tongues of the airbag housing, a fixing frame on the dashboard has corresponding undercuts, and therefore the fixed airbag module is connected to the tongues in a form-locking manner in the undercuts.

Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.

Abstract: The invention relates to the use of at least one oil-soluble compound B) which acts as a nucleating agent for paraffin crystallization and which is selected from ethylene copolymers and 2 to 10.5 mole % of at least one ethylenically unsaturated carbonic ester for improving the response of cold flow improvers for mineral oils C), which are different from B), in middle distillates that contain at least one ashless, nitrogenous detergent additive A), which is an oil-soluble, amphiphilic compound that comprises at least one alkyl or alkenyl group bound to a polar group, said alkyl or alkenyl group having 10 to 500 C atoms and the polar group having 2 or more nitrogen atoms.

Abstract: The invention relates to the use of at least one oil-soluble olefin copolymer B) which acts as a nucleating agent for paraffin crystallization for improving the response of cold flow improvers for mineral oils C), which are different from B), in middle distillates that contain at least one ashless, nitrogenous detergent additive A), which is an oil-soluble, amphiphilic compound that comprises at least one alkyl or alkenyl group bound to a polar group, said alkyl or alkenyl group having 10 to 500 C atoms and the polar group having 2 or more nitrogen atoms.

Abstract: The invention relates to the use of at least one oil-soluble compound B) which acts as a nucleating agent for paraffin crystallization and which is selected from substantially linear hydrocarbons with at least 22 C atoms, for improving the response of cold flow improvers for mineral oils C) in middle distillates that contain at least one ashless, nitrogenous detergent additive A), which is an oil-soluble, amphiphilic compound that comprises at least one alkyl or alkenyl group bound to a polar group, said alkyl or alkenyl group having 10 to 500 C atoms and the polar group having 2 or more nitrogen atoms.

Abstract: The invention provides for the use of at least one oil-soluble polyoxyalkylene compound, this polyoxyalkylene compound being an oil-soluble ester, ether or ether/ester of alkoxylated polyols having at least three repeat alkoxy units derived from alkylene oxides having from 2 to 5 carbon atoms per OH group of the polyol which bears at least two aliphatic hydrocarbon radicals having from 12 to 30 carbon atoms for improving the response behavior of mineral oil cold flow improvers in middle distillates which comprise at least one ashless, nitrogen-containing detergent additive which is an oil-soluble amphiphilic compound which comprises at least one alkyl or alkenyl radical which is bonded to a polar group, the alkyl or alkenyl radical comprising from 10 to 500 carbon atoms and the polar group comprising 2 or more nitrogen atoms.

Abstract: Ink coalescence in inkjet printing is reduced by printing mutually interstitial images using an arrangement of multiple curing stations in combination with multiple printing heads.

Abstract: An ink circulation system for use in an inkjet printing apparatus includes an inkjet printhead, an ink supply path for supplying an ink to the inkjet printhead and an ink return path for returning ink not used for printing from the inkjet printhead. The ink return path is coupled to the ink supply path for replenishing the ink supply path with the ink returned from the printhead. The coupling establishes an ink circulation circuit. The ink circulation circuit can be replenished with fresh ink from a main tank, as ink is withdrawn by the printhead for printing. In the circulation system an active through-flow ink degassing unit is provided to control the dissolved gas level of the ink in the ink circulation system.

Abstract: The invention relates to the use of at least one oil-soluble olefin copolymer B) which acts as a nucleating agent for paraffin crystallization for improving the response of cold flow improvers for mineral oils C), which are different from B), in middle distillates that contain at least one ashless, nitrogenous detergent additive A), which is an oil-soluble, amphiphilic compound that comprises at least one alkyl or alkenyl group bound to a polar group, said alkyl or alkenyl group having 10 to 500 C atoms and the polar group having 2 or more nitrogen atoms.

Abstract: The invention relates to the use of at least one oil-soluble compound B) which acts as a nucleating agent for paraffin crystallization and which is selected from ethylene copolymers and 2 to 10.5 mole-% of at least one ethylenically unsaturated carbonic ester for improving the response of cold flow improvers for mineral oils C), which are different from B), in middle distillates that contain at least one ashless, nitrogenous detergent additive A), which is an oil-soluble, amphiphilic compound that comprises at least one alkyl or alkenyl group bound to a polar group, said alkyl or alkenyl group having 10 to 500 C atoms and the polar group having 2 or more nitrogen atoms.

Abstract: The invention relates to the use of at least one oil-soluble compound B) which acts as a nucleating agent for paraffin crystallization and which is selected from comb polymers that carry alkyl side chains having on average a length of at least 18 C atoms per mole for improving the response of cold flow improvers for mineral oils C), which are different from B), in middle distillates that contain at least one ashless, nitrogenous detergent additive A), which is an oil-soluble, amphiphilic compound that comprises at least one alkyl or alkenyl group bound to a polar group, said alkyl or alkenyl group having 10 to 500 C atoms and the polar group having 2 or more nitrogen atoms.

Abstract: The invention relates to the use of at least one oil-soluble compound B) which acts as a nucleating agent for paraffin crystallization and which is selected from substantially linear hydrocarbons with at least 22 C atoms, for improving the response of cold flow improvers for mineral oils C) in middle distillates that contain at least one ashless, nitrogenous detergent additive A), which is an oil-soluble, amphiphilic compound that comprises at least one alkyl or alkenyl group bound to a polar group, said alkyl or alkenyl group having 10 to 500 C atoms and the polar group having 2 or more nitrogen atoms.